Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) shares traded up 2.6% during mid-day trading on Wednesday . The stock traded as high as $7.47 and last traded at $7.43, with a volume of 79,460 shares traded. The stock had previously closed at $7.24.

Several research analysts recently issued reports on the company. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th.

The stock’s market capitalization is $227.47 million. The company has a 50 day moving average of $6.55 and a 200-day moving average of $6.53.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.08. Equities analysts anticipate that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Foamix Pharmaceuticals stock. J. Goldman & Co LP boosted its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned approximately 1.90% of Foamix Pharmaceuticals worth $4,704,000 at the end of the most recent quarter.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.